Calliditas addresses the need of people with rare conditions – starting with treatment for renal and hepatic diseases. Today, Calliditas is the leading pharmaceutical company for treating renal diseases and develops treatment for inflammatory kidney disease as well as for Berger’s disease – the most common form of chronic kidney inflammation.
Industrifonden exited in 2024.